Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2015

Open Access 01-12-2015 | Research

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions

Authors: Ekin Ermiş, Mark Teo, Karen E. Dyker, Chris Fosker, Mehmet Sen, Robin JD Prestwich

Published in: Radiation Oncology | Issue 1/2015

Login to get access

Abstract

Introduction

A wide variety of fractionation schedules have been employed for the treatment of early glottic cancer. The aim is to report our 10-year experience of using hypofractionated radiotherapy with 55Gy in 20 fractions at 2.75Gy per fraction.

Methods

Patients treated between 2004 and 2013 with definitive radiotherapy to a dose of 55Gy in 20 fractions over 4 weeks for T1/2 N0 squamous cell carcinoma of the glottis were retrospectively identified. Patients with prior therapeutic minor surgery (eg. laser stripping, cordotomy) were included. The probabilities of local control, ultimate local control (including salvage surgery), regional control, cause specific survival (CSS) and overall survival (OS) were calculated.

Results

One hundred thirty-two patients were identified. Median age was 65 years (range 33–89). Median follow up was 72 months (range 7–124). 50 (38 %), 18 (14 %) and 64 (48 %) of patients had T1a, T1b and T2 disease respectively. Five year local control and ultimate local control rates were: overall - 85.6 % and 97.3 % respectively, T1a - 91.8 % and 100 %, T1b - 81.6 and 93.8 %, and T2 - 80.9 % and 95.8 %. Five year regional control, CSS and OS rates were 95.4 %, 95.7 % and 78.8 % respectively. There were no significant associations of covariates (e.g. T-stage, extent of laryngeal extension, histological grade) with local control on univariate analysis. Only increasing age and transglottic extension in T2 disease were significantly associated with overall survival (both p <0.01). Second primary cancers developed in 17 % of patients. 13 (9.8 %) of patients required enteral tube feeding support during radiotherapy; no patients required long term enteral nutrition. One patient required a tracheostomy due to a non-functioning larynx on long term follow up.

Conclusions

Hypofractionated radiation therapy with a dose of 55Gy in 20 fractions for early stage glottic cancer provides high rates of local control with acceptable toxicity.
Literature
1.
2.
3.
Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100(9):1786–92.CrossRefPubMed
4.
Luscher MS, Pedersen U, Johansen LV. Treatment outcome after laser excision of early glottic squamous cell carcinoma--a literature survey. Acta Oncol. 2001;40(7):796–800.CrossRefPubMed
5.
Delsupehe KG, Zink I, Lejaegere M, Bastian RW. Voice quality after narrow-margin laser cordectomy compared with laryngeal irradiation. Otolaryngol Head Neck Surg. 1999;121(5):528–33.CrossRefPubMed
6.
Mendenhall WM, Mancuso AA, Hinerman RW, Malyapa RS, Werning JW, Amdur RJ, et al. Multidisciplinary management of laryngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S12–4.CrossRefPubMed
7.
Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001;19(20):4029–36.PubMed
8.
Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006;64(1):77–82.CrossRefPubMed
9.
Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997;39(1):115–26.CrossRefPubMed
10.
Trotti 3rd A, Zhang Q, Bentzen SM, Emami B, Hammond ME, Jones CU, et al. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys. 2014;89(5):958–63.CrossRefPubMed
11.
Cheah NL, Lupton S, Marshall A, Hartley A, Glaholm J. Outcome of T1N0M0 squamous cell carcinoma of the larynx treated with short-course radiotherapy to a total dose of 50 Gy in 16 fractions: the Birmingham experience. Clin Oncol (R Coll Radiol). 2009;21(6):494–501.CrossRef
12.
Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. Radiother Oncol. 2003;68(2):105–11.CrossRefPubMed
13.
Royal College of Radiologists U. Radiotherapy dose fractionation. 2006.
14.
James ND, Robertson G, Squire CJ, Forbes H, Jones K, Cottier B. A national audit of radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol). 2003;15(2):41–6.CrossRef
15.
Williams MV, James ND, Summers ET, Barrett A, Ash DV. National survey of radiotherapy fractionation practice in. Clin Oncol (R Coll Radiol) 2006. 2003;18(1):3–14.CrossRef
16.
Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(2):461–6.CrossRefPubMed
17.
ICRU 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, USA: International Commission on Radiation Units and Measurements Press; 1993.
18.
Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol. 2003;69(2):161–8.CrossRefPubMed
19.
Meade S, Sanghera P, McConkey C, Fowler J, Fountzilas G, Glaholm J, et al. Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. Int J Radiat Oncol Biol Phys. 2013;86(1):157–63.CrossRefPubMed
20.
Hartley A, Sanghera P, Kazi W, Mehanna H, McConkey C, Glaholm J, et al. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer. Clin Oncol (R Coll Radiol). 2011;23(1):29–33.CrossRef
21.
Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2007;67(5):1342–51.CrossRefPubMed
22.
Roberts SA, Hendry JH, Brewster AE, Slevin NJ. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol. 1994;67(800):790–4.CrossRefPubMed
23.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 6th Ed. New York: Springer Verlag; 2002.
24.
Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th Ed. New York: Springer Verlag; 2007.
25.
Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP et al. AJCC Cancer Staging Handbook from AJCC Cancer Staging Manual, 5th Ed. Philadelphia: Lippincott-Raven; 1998.
26.
Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol. 2014;110(1):98–103.CrossRefPubMed
27.
Kim TG, Ahn YC, Nam HR, Chung MK, Jeong HS, Son YI, et al. Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules. Clin Exp Otorhinolaryngol. 2012;5(2):94–100.PubMedCentralCrossRefPubMed
28.
Laskar SG, Baijal G, Murthy V, Chilukuri S, Budrukkar A, Gupta T, et al. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution. Clin Oncol (R Coll Radiol). 2012;24(10):e180–6.CrossRef
29.
Short S, Krawitz H, Macann A, West T, Morton RP, McIvor NP, et al. TN/TN glottic carcinoma: a comparison of two fractionation schedules. Australas Radiol. 2006;50(2):152–7.CrossRefPubMed
30.
Jamshed AHR, Rehman K, Iqbal H, Ali M, Jamshed S, Hameed N, et al. Hypofractionated radiotherapy in the treatment of early glottic cancer. Int J Head Neck Surg. 2011;2:138–43.CrossRef
31.
Warde P, O’Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 1998;41(2):347–53.CrossRefPubMed
32.
33.
Khan MK, Koyfman SA, Hunter GK, Reddy CA, Saxton JP. Definitive radiotherapy for early (T1-T2) glottic squamous cell carcinoma: a 20 year Cleveland Clinic experience. Radiat Oncol. 2012;7:193.PubMedCentralCrossRefPubMed
34.
Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, et al. Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer. 2003;98(4):765–72.CrossRefPubMed
35.
Kazi R, Venkitaraman R, Johnson C, Prasad V, Clarke P, Newbold K, et al. Prospective, longitudinal electroglottographic study of voice recovery following accelerated hypofractionated radiotherapy for T1/T2 larynx cancer. Radiother Oncol. 2008;87(2):230–6.CrossRefPubMed
36.
Janssen S, Glanzmann C, Huber G, Studer G. Risk-adapted partial larynx and/or carotid artery sparing modulated radiation therapy of glottic cancer. Radiat Oncol. 2014;9:136.PubMedCentralCrossRefPubMed
Metadata
Title
Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions
Authors
Ekin Ermiş
Mark Teo
Karen E. Dyker
Chris Fosker
Mehmet Sen
Robin JD Prestwich
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2015
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-015-0505-6

Other articles of this Issue 1/2015

Radiation Oncology 1/2015 Go to the issue

Research

In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study

Research

Distribution pattern of lymph node metastases and its implication in individualized radiotherapeutic clinical target volume delineation of regional lymph nodes in patients with stage IA to IIA cervical cancer

Research

Palliative radiotherapy with or without additional care by a multidisciplinary palliative care team in patients with newly diagnosed cancer: a retrospective matched pairs comparison

Research

Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy

Research

Validation of Varian’s SmartAdapt® deformable image registration algorithm for clinical application

Research

Geometric changes of parotid glands caused by hydration during chemoradiotherapy